ClinicalTrials.gg
CompletedNCT04928573Updated Oct 12, 2023

Study for Late Assessment of the Safety and Efficacy of Biosimilar Rituximab

An observational study in Diffuse Large B Cell Lymphoma, sponsored by Libbs Farmacêutica LTDA. Completed at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Libbs Farmacêutica LTDA · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
27
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Lymphoma, Large B-Cell, Diffuse with a site in Brazil — 8 open to participants now, 14 under way, 8 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Brazil.

Started
2022
with 1 other
Observational
3 of 28
1 open now
Registered
16th of 28
by date

Among the 28 studies in Lymphoma, Large B-Cell, Diffuse with a site in Brazil, this one is one of 2 that started in 2022, is one of 3 observational ones, and was the 16th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

8 of the 28 studies in Lymphoma, Large B-Cell, Diffuse with a site in Brazil are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Lymphoma, Large B-Cell, Diffuse with a site in Brazil, or all of them as a file.
02

Study summary

The RTXM83-AC-01-11 study evaluated efficacy and safety outcomes in relation to the use of Vivaxxia during 6 treatment cycles (at the investigator's discretion, up to 8 treatment cycles could be administered), followed by 9 months of follow-up. , this follow-up time being sufficient for the analysis of non-inferiority in relation to the reference medicine. However, data on late events of efficacy and safety are of great value to contribute to a robust clinical response and to strengthen confidence in the use of biosimilar medicines. For this reason, Libbs Farmacêutica proposes this retrospective observational study to collect data on late outcomes of the pivotal study that directed the approval of the biosimilar rituximab (Vivaxxia) from the research participants from Brazil.

The present retrospective observational study LB2002 will sub-analyze selected results of efficacy and safety from study RTXM83-AC-01-11 in participants over 18 years of age randomized in Brazil, totaling 28 participants, in addition to evaluating late efficacy and safety outcomes. Information on subsequent treatment / protocol should also be collected for participants who have progressive or recurrent disease, instituted by research centers under these conditions.

The proposal is to compare descriptively the selected outcomes of efficacy and safety of these participants with the same outcomes selected for the global population in the RTXM83-AC-01-11 study, and also provide late safety and effective data important for anti-neoplastic processes.

Read the detailed description

Evaluate research participants who were refractory to treatment, defined as not having achieved: Complete Response (CR) or Partial Response (PR), after 6 treatment cycles in study RTXM83-AC-01-11.

Evaluate the participants who had a recurrence of the disease, defined as a change from: Complete Response (CR), after 06 treatment cycles in study RTXM83-AC-01-11, to: Progressive Disease (PD) until the date of consent (ICF) in the LB2002 study.

The data of the subsequent treatment / protocol instituted by the research center for progressive or recurrent disease will also be collected.

PERIOD OF ANALYSIS OF THIS CLINICAL STUDY

  • 01-JUL-2013 (beginning of the study) to 17-JUL-2017 (data in which the last participant of the study RTXM83-AC-01-11 arrived at the last follow-up visit at 9 months after the last dose of treatment): for sub-analysis of efficacy and safety proposed by study RTXM83-AC-01-11: SLE, TRG and EA, and for exploratory evaluation of refractory disease.
  • Data from randomization in study RTXM83-AC-01-11 to consent data (TCLE) in study LB2002: for analysis of SLP, SG and for exploratory evaluation of relapse.
  • Date of the final visit of study RTXM83-AC-01-11, considered as FUP3, until the date of consent (ICF) in study LB2002: for the evaluation of late AEs of interest.

Data collect:For the subanalysis evaluations, the data that have already been collected will be used and are part of the study database RTXM83-AC-01-11. This database will also be considered for exploratory assessment of refractory disease.

For late evaluations of safety and efficacy (late adverse events of interest, SLP, SG and disease recurrence) and also data on the subsequent treatment / protocol instituted by the research center for progressive disease or disease recurrence, data from medical records available at research centers.

Finally, all the data necessary to evaluate the objectives established in this study will be imputed in a single Electronic Case Report Form (eCRF) developed exclusively for this project.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma

Keywords

  • rituximab
  • Vivaxxia
  • Diffuse Large B Cell Lymphoma
  • biosimilar
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11, already completed, will be eligible for this observational, retrospective study LB2002, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries.

The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of diffuse large B cell lymphoma (LDGCB) CD20 positive.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Free and to participate in this retrospective, observational study of data collection
  • Research participants from Brazil randomized and who received at least one dose of treatment in the RTXM83-AC-01-11 study.

Exclusion criteria

Exclusion Criteria:

  • not applicable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • Group I

    All participants previously randomized in Brazil for the phase III study RTXM83-AC-01-11 already completed, which was conducted to support the registration of the new biosimilar of rituximab (Vivaxxia) in different countries. The RTXM83-AC-01-11 study compared the efficacy and safety between biosimilar rituximab (RTXM83) and the reference rituximab (Mabthera®), both associated with CHOP chemotherapy (RTXM83-CHOP and R-CHOP, respectively) and included participants of the research with a diagnosis of lymphoma other than large B cell (LDGCB) CD20 positive.

06

What researchers measure

Primary outcomes

  1. Effectiveness evaluation: subanalysis of event-free survival

    To present the subanalysis of event-free survival of participants from Brazil in the two treatment groups (RTXM83-CHOP and R-CHOP) from the randomization date until the final visit of the RTXM83-AC-01-11 study, considered as o FUP 3 (9-month follow-up after the end of treatment);

    Time frame: 9 months after treatment

  2. Effectiveness evaluation: subanalysis of the Global Response Rate

    To present the subanalysis of the Global Response Rate of participants from Brazil in the two treatment groups (RTXM83-CHOP and R-CHOP), after 6 treatment cycles in the RTXM83-AC-01-11 study, assessed as Complete Response ( RC) or Partial Response (PR);

    Time frame: At the end of Cycle 6 (each cycle is 03 weeks)

  3. Security evaluation: sub-analysis of the adverse events

    Present the sub-analysis of the adverse events (AE) of the participants in Brazil that occurred from the date of signing the Free and Informed Consent Form (ICF) until the final visit of the study RTXM83-AC-01-11, considered as the FUP 3 (follow-up) 9 months after the end of treatment);

    Time frame: 9 months after treatment

  4. Effectiveness evaluation: progression-free survival

    Assess progression-free survival in the two treatment groups (RTXM83-CHOP and R-CHOP) from the date of randomization in the RTXM83-AC-01-11 study until the date of consent (ICF) in the LB2002 study;

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 96 months

  5. Effectiveness evaluation: Assess the overall survival

    Assess the overall survival in the two treatment groups (RTXM83-CHOP and R-CHOP) from the date of randomization in study RTXM83-AC-01-11 until the date of consent (ICF) in study LB2002;

    Time frame: From date of randomization until the date of death from any cause, assessed up to 96 months

  6. Security evaluation: occurrence of late adverse events

    Evaluate the occurrence of late adverse events of interest from the date of the final visit of the RTXM83-AC-01-11 study, considered as FUP 3, until the date of consent (TCLE) in the LB2002 study.

    Time frame: From date of randomization until the date of death from any cause, assessed up to 96 months

07

Study locations

1 site
  • Dr Fernando Pericole
    Campinas, São Paulo 13083-878, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jul 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2021
First posted
Jun 16, 2021
StartActual
Feb 8, 2022
Primary completionActual
Jul 29, 2022
CompletionActual
Mar 23, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04928573
Lead sponsor
Libbs Farmacêutica LTDA
Responsible party
Sponsor
First posted
Jun 16, 2021
Start date
Feb 8, 2022
Primary completion
Jul 29, 2022
Completion
Mar 23, 2023
Last update
Oct 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion